{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:36Z","timestamp":1793291616245,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":276,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41391-026-01140-5","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:02:09Z","timestamp":1785841329000},"page":"1013-1018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Germline genetic risk and prostate cancer\u2013specific mortality in a population-based incident cohort"],"prefix":"10.1038","volume":"29","author":[{"given":"Lucy","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Engelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pieczonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Lilly","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Helfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-473X","authenticated-orcid":false,"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-8752","authenticated-orcid":false,"given":"Jianfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate Cancer: A Review. JAMA. 2025;333:1433\u201346.","journal-title":"JAMA"},{"key":"1140_CR2","unstructured":"National Cancer Institute. Cancer facts: prostate cancer: SEER; 2026. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"1140_CR3","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1001\/jamaoncol.2020.4922","volume":"6","author":"RT Dess","year":"2020","unstructured":"Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, et al. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020;6:1912\u201320.","journal-title":"JAMA Oncol"},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines(R) Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:140\u201350.","journal-title":"J Natl Compr Canc Netw"},{"key":"1140_CR5","doi-asserted-by":"publisher","first-page":"e1002063","DOI":"10.1371\/journal.pmed.1002063","volume":"13","author":"VJ Gnanapragasam","year":"2016","unstructured":"Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study. PLoS Med. 2016;13:e1002063.","journal-title":"PLoS Med"},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/cncr.33584","volume":"127","author":"AB Weiner","year":"2021","unstructured":"Weiner AB, Li EV, Desai AS, Press DJ, Schaeffer EM. Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis. Cancer. 2021;127:2895\u2013904.","journal-title":"Cancer"},{"key":"1140_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388:1547\u201358.","journal-title":"N Engl J Med"},{"key":"1140_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMra1910138","volume":"381","author":"J Nangalia","year":"2019","unstructured":"Nangalia J, Campbell PJ. Genome Sequencing during a Patient\u2019s Journey through Cancer. N Engl J Med. 2019;381:2145\u201356.","journal-title":"N Engl J Med"},{"key":"1140_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398:1075\u201390.","journal-title":"Lancet"},{"key":"1140_CR10","unstructured":"Cheng HH Genetic risk factors for prostate cancer: UpToDate; https:\/\/www.uptodate.com\/contents\/genetic-risk-factors-for-prostate-cancer. (2024)."},{"key":"1140_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"1140_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","volume":"71","author":"R Na","year":"2017","unstructured":"Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, et al. Germline Mutations in ATM and BRCA1\/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017;71:740\u20137.","journal-title":"Eur Urol"},{"key":"1140_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","volume":"75","author":"HB Carter","year":"2019","unstructured":"Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, et al. Germline Mutations in ATM and BRCA1\/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur Urol. 2019;75:743\u20139.","journal-title":"Eur Urol"},{"key":"1140_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euo.2019.12.003","volume":"3","author":"Y Wu","year":"2020","unstructured":"Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, et al. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. Eur Urol Oncol. 2020;3:224\u201330.","journal-title":"Eur Urol Oncol"},{"key":"1140_CR15","doi-asserted-by":"crossref","unstructured":"Darst BF, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, et al. Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer. J Natl Cancer Inst. 2021;113:616\u201325.","DOI":"10.1093\/jnci\/djaa132"},{"key":"1140_CR16","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","volume":"9","author":"BF Darst","year":"2023","unstructured":"Darst BF, Saunders E, Dadaev T, Sheng X, Wan P, Pooler L, et al. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. JAMA Oncol. 2023;9:1514\u201324.","journal-title":"JAMA Oncol"},{"key":"1140_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/1078-0432.CCR-24-2483","volume":"31","author":"KH Stopsack","year":"2025","unstructured":"Stopsack KH, Vijai J, Conry M, Berchuck JE, Kemel Y, Vasselman SE, et al. Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer. Clin Cancer Res. 2025;31:122\u20139.","journal-title":"Clin Cancer Res"},{"key":"1140_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56944-1","volume":"16","author":"J Mitchell","year":"2025","unstructured":"Mitchell J, Camacho N, Shea P, Stopsack KH, Joseph V, Burren OS, et al. Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. Nat Commun. 2025;16:1779.","journal-title":"Nat Commun"},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/pros.24918","volume":"85","author":"J Xu","year":"2025","unstructured":"Xu J, Lu J, Gielzak M, Lilly Zheng S, Lu L, Wei J, et al. Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines. Prostate. 2025;85:1087\u201395.","journal-title":"Prostate"},{"key":"1140_CR20","doi-asserted-by":"crossref","unstructured":"Xu J, Shi Z, Wei J, Na R, Resurreccion WK, Wang CH, et al. KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression. Prostate Cancer Prostatic Dis. 2022;25:749\u201354.","DOI":"10.1038\/s41391-021-00466-6"},{"key":"1140_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52472-6","volume":"15","author":"S Srinivasan","year":"2024","unstructured":"Srinivasan S, Kryza T, Bock N, Tse BWC, Sokolowski KA, Janaththani P, et al. A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. Nat Commun. 2024;15:9587.","journal-title":"Nat Commun"},{"key":"1140_CR22","doi-asserted-by":"publisher","first-page":"e242976","DOI":"10.1001\/jamanetworkopen.2024.2976","volume":"7","author":"RR McKay","year":"2024","unstructured":"McKay RR, Nelson TJ, Pagadala MS, Teerlink CC, Gao A, Bryant AK, et al. Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes. JAMA Netw Open. 2024;7:e242976.","journal-title":"JAMA Netw Open"},{"key":"1140_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41585-024-00953-0","volume":"22","author":"PFS Freitas","year":"2025","unstructured":"Freitas PFS, Abdshah A, McKay RR, Sharifi N. HSD3B1, prostate cancer mortality and modifiable outcomes. Nat Rev Urol. 2025;22:313\u201320.","journal-title":"Nat Rev Urol"},{"key":"1140_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","volume":"53","author":"DV Conti","year":"2021","unstructured":"Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53:65\u201375.","journal-title":"Nat Genet"},{"key":"1140_CR25","doi-asserted-by":"crossref","unstructured":"Dornisch AM, Xu GJ, Karunamuni R, Brunette CA, Danowski ME, Teerlink CC, et al. Specificity of a polygenic score for aggressive prostate cancer. medRxiv, 2025.","DOI":"10.1101\/2025.01.23.25321041"},{"key":"1140_CR26","doi-asserted-by":"publisher","unstructured":"Hu J, Ye Y, Zhou G, Zhao H. Using clinical and genetic risk factors for risk prediction of 8 cancers in the UK Biobank. JNCI Cancer Spectr 2024;8, https:\/\/doi.org\/10.1093\/jncics\/pkae008.","DOI":"10.1093\/jncics\/pkae008"},{"key":"1140_CR27","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ajhg.2023.05.010","volume":"110","author":"BF Darst","year":"2023","unstructured":"Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, et al. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Am J Hum Genet. 2023;110:1200\u20136.","journal-title":"Am J Hum Genet"},{"key":"1140_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203\u20139.","journal-title":"Nature"},{"key":"1140_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2017.01.004","volume":"100","author":"Q Li","year":"2017","unstructured":"Li Q, Wang K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. Am J Hum Genet. 2017;100:267\u201380.","journal-title":"Am J Hum Genet"},{"key":"1140_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"1140_CR31","unstructured":"Clinical Genome Resource. Sequence Variant Interpretation 2025; cited 2025 Sep]. https:\/\/clinicalgenome.org\/working-groups\/sequence-variant-interpretation\/."},{"key":"1140_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41588-021-00783-5","volume":"53","author":"SA Lambert","year":"2021","unstructured":"Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, et al. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat Genet. 2021;53:420\u20135.","journal-title":"Nat Genet"},{"key":"1140_CR33","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","volume":"7","author":"FY Feng","year":"2021","unstructured":"Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG\/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021;7:544\u201352.","journal-title":"JAMA Oncol"},{"key":"1140_CR34","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1210\/en.2019-00366","volume":"160","author":"N Sabharwal","year":"2019","unstructured":"Sabharwal N, Sharifi N. HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond. Endocrinology. 2019;160:2180\u20138.","journal-title":"Endocrinology"},{"key":"1140_CR35","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.annonc.2020.06.006","volume":"31","author":"DJ Khalaf","year":"2020","unstructured":"Khalaf DJ, Aragon IM, Annala M, Lozano R, Taavitsainen S, Lorente D, et al. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Ann Oncol. 2020;31:1186\u201397.","journal-title":"Ann Oncol"},{"key":"1140_CR36","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.annonc.2020.04.473","volume":"31","author":"C Lu","year":"2020","unstructured":"Lu C, Terbuch A, Dolling D, Yu J, Wang H, Chen Y, et al. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. Ann Oncol. 2020;31:1178\u201385.","journal-title":"Ann Oncol"},{"key":"1140_CR37","doi-asserted-by":"publisher","first-page":"e196496","DOI":"10.1001\/jamaoncol.2019.6496","volume":"6","author":"JWD Hearn","year":"2020","unstructured":"Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, et al. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncol. 2020;6:e196496.","journal-title":"JAMA Oncol"},{"key":"1140_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/pros.70089","volume":"86","author":"R Shi","year":"2026","unstructured":"Shi R, Du Q, Yao C, Huang D, Ruan X, Lam ACY, et al. The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients. Prostate. 2026;86:329\u201337.","journal-title":"Prostate"},{"key":"1140_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101644","volume":"5","author":"N Sharifi","year":"2024","unstructured":"Sharifi N, Azad AA, Patel M, Hearn JWD, Wozniak M, Zohren F, et al. HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES. Cell Rep Med. 2024;5:101644.","journal-title":"Cell Rep Med"},{"key":"1140_CR40","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.7150\/jca.31454","volume":"10","author":"J Wang","year":"2019","unstructured":"Wang J, Xu WH, Wei Y, Zhu Y, Qin XJ, Zhang HL, et al. Elevated MRE11 expression associated with progression and poor outcome in prostate cancer. J Cancer. 2019;10:4333\u201340.","journal-title":"J Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01140-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:09Z","timestamp":1793289789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01140-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01140-5","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Endeavor Health has agreements with GenomicMD and GoPath Diagnostics for genetic tests of polygenic risk scores. J. Xu serves a scientific advisory board member for GoPath Diagnostics and GenomicMD.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This research has been conducted using the UK Biobank Resource under Application Number 50295. All methods were performed in accordance with the relevant guidelines and regulations. The UK Biobank study received ethical approval from the North West Multi-centre Research Ethics Committee (reference 11\/NW\/0382), and all UK Biobank participants provided informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}